{"id":64323,"date":"2026-04-30T14:57:34","date_gmt":"2026-04-30T06:57:34","guid":{"rendered":"https:\/\/flcube.com\/?p=64323"},"modified":"2026-04-30T14:57:34","modified_gmt":"2026-04-30T06:57:34","slug":"abbvie-reports-12-4-revenue-growth-in-q1-2026-driven-by-immunology-and-neuroscience-strength","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64323","title":{"rendered":"AbbVie Reports 12.4% Revenue Growth in Q1 2026 Driven by Immunology and Neuroscience Strength"},"content":{"rendered":"\n<p><strong>AbbVie Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/ABBV:NYSE\">NYSE: ABBV<\/a>) reported <strong>first quarter 2026 financial results<\/strong> with <strong>worldwide net revenues of USD 15.002 billion<\/strong>, representing <strong>12.4% growth on a reported basis<\/strong>. The strong performance was led by robust growth in the <strong>immunology portfolio (+16.4%)<\/strong> and <strong>neuroscience segment (+26.0%)<\/strong>, offsetting declines in aesthetics and continued Humira erosion in international markets.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-highlights-q1-2026\">Financial Highlights \u2013 Q1 2026<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Q1 2026<\/th><th>YOY Change<\/th><\/tr><\/thead><tbody><tr><td><strong>Worldwide Net Revenues<\/strong><\/td><td>USD 15.002 billion<\/td><td>+12.4%<\/td><\/tr><tr><td><strong>Immunology Portfolio<\/strong><\/td><td>USD 7.290 billion<\/td><td>+16.4%<\/td><\/tr><tr><td><strong>Neuroscience Portfolio<\/strong><\/td><td>USD 2.875 billion<\/td><td>+26.0%<\/td><\/tr><tr><td><strong>Oncology Sales<\/strong><\/td><td>USD 1.631 billion<\/td><td>-0.2%<\/td><\/tr><tr><td><strong>Aesthetics Portfolio<\/strong><\/td><td>USD 1.186 billion<\/td><td>-7.6%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-immunology-portfolio-performance\">Immunology Portfolio Performance<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>Q1 2026 Revenue<\/th><th>YOY Change<\/th><\/tr><\/thead><tbody><tr><td><strong>Skyrizi (risankizumab)<\/strong><\/td><td>USD 4.483 billion<\/td><td>+30.9%<\/td><\/tr><tr><td><strong>Rinvoq (upadacitinib)<\/strong><\/td><td>USD 2.119 billion<\/td><td>+23.3%<\/td><\/tr><tr><td><strong>Humira (adalimumab)<\/strong><\/td><td>USD 688 million<\/td><td>-38.6%<\/td><\/tr><tr><td><strong>Total Immunology<\/strong><\/td><td>USD 7.290 billion<\/td><td>+16.4%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-key-dynamics\">Key Dynamics<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Skyrizi<\/strong> continues exceptional growth trajectory across psoriasis, psoriatic arthritis, and Crohn&#8217;s disease indications<\/li>\n\n\n\n<li><strong>Rinvoq<\/strong> demonstrates sustained momentum in rheumatoid arthritis and atopic dermatitis markets<\/li>\n\n\n\n<li><strong>Humira<\/strong> decline reflects expected biosimilar competition impact outside the U.S., where exclusivity expired in 2023<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-neuroscience-portfolio-breakdown\">Neuroscience Portfolio Breakdown<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>Q1 2026 Revenue<\/th><th>YOY Change<\/th><\/tr><\/thead><tbody><tr><td><strong>Botox Therapeutic<\/strong><\/td><td>USD 1.009 billion<\/td><td>+16.5%<\/td><\/tr><tr><td><strong>Vraylar (cariprazine)<\/strong><\/td><td>USD 905 million<\/td><td>+18.4%<\/td><\/tr><tr><td><strong>Ubrelvy (ubrogepant)<\/strong><\/td><td>USD 339 million<\/td><td>+41.4%<\/td><\/tr><tr><td><strong>Qulipta (atogepant)<\/strong><\/td><td>USD 296 million<\/td><td>+53.6%<\/td><\/tr><tr><td><strong>Total Neuroscience<\/strong><\/td><td>USD 2.875 billion<\/td><td>+26.0%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-growth-drivers\">Growth Drivers<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Migraine franchise<\/strong> shows explosive growth with both Ubrelvy and Qulipta exceeding 40% year-over-year increases<\/li>\n\n\n\n<li><strong>Botox Therapeutic<\/strong> maintains strong growth in chronic migraine, spasticity, and therapeutic applications<\/li>\n\n\n\n<li><strong>Vraylar<\/strong> continues steady expansion in bipolar disorder and schizophrenia markets<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-business-segment-analysis\">Business Segment Analysis<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Segment<\/th><th>Performance Summary<\/th><\/tr><\/thead><tbody><tr><td><strong>Immunology<\/strong><\/td><td>Core growth engine with Skyrizi and Rinvoq successfully offsetting Humira erosion<\/td><\/tr><tr><td><strong>Neuroscience<\/strong><\/td><td>Emerging powerhouse with diversified portfolio across psychiatry, neurology, and migraine<\/td><\/tr><tr><td><strong>Oncology<\/strong><\/td><td>Stable performance despite competitive pressures in hematologic malignancies<\/td><\/tr><tr><td><strong>Aesthetics<\/strong><\/td><td>Temporary decline likely reflecting seasonal patterns and inventory adjustments<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications-amp-market-outlook\">Strategic Implications &amp; Market Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Portfolio Diversification Success<\/strong>: AbbVie&#8217;s strategic shift from Humira dependency to multi-franchise model is delivering sustainable growth<\/li>\n\n\n\n<li><strong>Immunology Leadership<\/strong>: Skyrizi and Rinvoq combination positions AbbVie as dominant player in next-generation immunology therapeutics<\/li>\n\n\n\n<li><strong>Neuroscience Expansion<\/strong>: Migraine franchise emergence creates new high-growth pillar complementing established Botox and Vraylar franchises<\/li>\n\n\n\n<li><strong>Financial Resilience<\/strong>: Strong cash flow generation supports continued R&amp;D investment and shareholder returns<\/li>\n\n\n\n<li><strong>Competitive Moat<\/strong>: Proprietary biologics and small molecules with strong clinical differentiation maintain pricing power despite biosimilar pressures<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding financial performance, product growth trajectories, and market dynamics. Actual results may differ due to risks including competitive pressures, regulatory developments, pricing pressures, and market adoption rates for newer products.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/ABBV-1Q26-Press-Release-Final.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of ABBV 1Q26 Press Release - Final.\"><\/object><a id=\"wp-block-file--media-f47de1d0-2529-4d7f-a2be-15565a54378a\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/ABBV-1Q26-Press-Release-Final.pdf\">ABBV 1Q26 Press Release &#8211; Final<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/ABBV-1Q26-Press-Release-Final.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-f47de1d0-2529-4d7f-a2be-15565a54378a\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>AbbVie Inc. (NYSE: ABBV) reported first quarter 2026 financial results with worldwide net revenues of&#8230;<\/p>\n","protected":false},"author":1,"featured_media":64326,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[234,27,853],"class_list":["post-64323","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-abbvie","tag-finanical-reports","tag-nyse-abbv"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AbbVie Reports 12.4% Revenue Growth in Q1 2026 Driven by Immunology and Neuroscience Strength - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"AbbVie Inc. (NYSE: ABBV) reported first quarter 2026 financial results with worldwide net revenues of USD 15.002 billion, representing 12.4% growth on a reported basis. The strong performance was led by robust growth in the immunology portfolio (+16.4%) and neuroscience segment (+26.0%), offsetting declines in aesthetics and continued Humira erosion in international markets.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64323\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AbbVie Reports 12.4% Revenue Growth in Q1 2026 Driven by Immunology and Neuroscience Strength\" \/>\n<meta property=\"og:description\" content=\"AbbVie Inc. (NYSE: ABBV) reported first quarter 2026 financial results with worldwide net revenues of USD 15.002 billion, representing 12.4% growth on a reported basis. The strong performance was led by robust growth in the immunology portfolio (+16.4%) and neuroscience segment (+26.0%), offsetting declines in aesthetics and continued Humira erosion in international markets.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64323\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-30T06:57:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/3004.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64323#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64323\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AbbVie Reports 12.4% Revenue Growth in Q1 2026 Driven by Immunology and Neuroscience Strength\",\"datePublished\":\"2026-04-30T06:57:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64323\"},\"wordCount\":403,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64323#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/3004.webp\",\"keywords\":[\"AbbVie\",\"Finanical Reports\",\"NYSE: ABBV\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64323#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64323\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64323\",\"name\":\"AbbVie Reports 12.4% Revenue Growth in Q1 2026 Driven by Immunology and Neuroscience Strength - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64323#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64323#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/3004.webp\",\"datePublished\":\"2026-04-30T06:57:34+00:00\",\"description\":\"AbbVie Inc. (NYSE: ABBV) reported first quarter 2026 financial results with worldwide net revenues of USD 15.002 billion, representing 12.4% growth on a reported basis. The strong performance was led by robust growth in the immunology portfolio (+16.4%) and neuroscience segment (+26.0%), offsetting declines in aesthetics and continued Humira erosion in international markets.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64323#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64323\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64323#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/3004.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/3004.webp\",\"width\":1080,\"height\":608,\"caption\":\"AbbVie Reports 12.4% Revenue Growth in Q1 2026 Driven by Immunology and Neuroscience Strength\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64323#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AbbVie Reports 12.4% Revenue Growth in Q1 2026 Driven by Immunology and Neuroscience Strength\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AbbVie Reports 12.4% Revenue Growth in Q1 2026 Driven by Immunology and Neuroscience Strength - Insight, China&#039;s Pharmaceutical Industry","description":"AbbVie Inc. (NYSE: ABBV) reported first quarter 2026 financial results with worldwide net revenues of USD 15.002 billion, representing 12.4% growth on a reported basis. The strong performance was led by robust growth in the immunology portfolio (+16.4%) and neuroscience segment (+26.0%), offsetting declines in aesthetics and continued Humira erosion in international markets.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64323","og_locale":"en_US","og_type":"article","og_title":"AbbVie Reports 12.4% Revenue Growth in Q1 2026 Driven by Immunology and Neuroscience Strength","og_description":"AbbVie Inc. (NYSE: ABBV) reported first quarter 2026 financial results with worldwide net revenues of USD 15.002 billion, representing 12.4% growth on a reported basis. The strong performance was led by robust growth in the immunology portfolio (+16.4%) and neuroscience segment (+26.0%), offsetting declines in aesthetics and continued Humira erosion in international markets.","og_url":"https:\/\/flcube.com\/?p=64323","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-30T06:57:34+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/3004.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64323#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64323"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AbbVie Reports 12.4% Revenue Growth in Q1 2026 Driven by Immunology and Neuroscience Strength","datePublished":"2026-04-30T06:57:34+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64323"},"wordCount":403,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=64323#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/3004.webp","keywords":["AbbVie","Finanical Reports","NYSE: ABBV"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64323#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64323","url":"https:\/\/flcube.com\/?p=64323","name":"AbbVie Reports 12.4% Revenue Growth in Q1 2026 Driven by Immunology and Neuroscience Strength - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=64323#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=64323#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/3004.webp","datePublished":"2026-04-30T06:57:34+00:00","description":"AbbVie Inc. (NYSE: ABBV) reported first quarter 2026 financial results with worldwide net revenues of USD 15.002 billion, representing 12.4% growth on a reported basis. The strong performance was led by robust growth in the immunology portfolio (+16.4%) and neuroscience segment (+26.0%), offsetting declines in aesthetics and continued Humira erosion in international markets.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64323#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64323"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=64323#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/3004.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/3004.webp","width":1080,"height":608,"caption":"AbbVie Reports 12.4% Revenue Growth in Q1 2026 Driven by Immunology and Neuroscience Strength"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64323#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AbbVie Reports 12.4% Revenue Growth in Q1 2026 Driven by Immunology and Neuroscience Strength"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/3004.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64323","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64323"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64323\/revisions"}],"predecessor-version":[{"id":64327,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64323\/revisions\/64327"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/64326"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64323"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64323"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64323"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}